XTL BIOPHARMACEUTICALS LTD

XTL Biopharmaceuticals Ltd.

Biotechnology Healthcare Ramat Gan, Israel XTLB (NCM)

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. The company has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.

Stock Performance (90 Days)

Data through Dec 29, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Other Biotechnology Companies

View All →

Frequently Asked Questions

Has XTL BIOPHARMACEUTICALS LTD had layoffs?
No layoff events have been recorded for XTL BIOPHARMACEUTICALS LTD in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does XTL BIOPHARMACEUTICALS LTD have?
XTL BIOPHARMACEUTICALS LTD has approximately 10 employees.
What industry is XTL BIOPHARMACEUTICALS LTD in?
XTL BIOPHARMACEUTICALS LTD operates in the Biotechnology industry, within the Healthcare sector.
Is XTL BIOPHARMACEUTICALS LTD a publicly traded company?
Yes, XTL BIOPHARMACEUTICALS LTD is publicly traded under the ticker symbol XTLB on the NCM. The company has a market capitalization of approximately $0.01 billion.
Where is XTL BIOPHARMACEUTICALS LTD headquartered?
XTL BIOPHARMACEUTICALS LTD is headquartered in Ramat Gan, Israel at 26 Ben-Gurion St., Israel.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.